Publications by authors named "M Zazzi"
Article Synopsis
- The study aimed to determine if switching from dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) reduces neuropsychiatric symptoms in HIV patients.
- Conducted as a randomized trial, it involved 41 participants who had been stable on DTG/ABC/3TC and compared those who switched to BIC/FTC/TAF versus those who continued their current therapy.
- Results indicated that switching improved sleep disorders among participants but did not significantly impact other neuropsychiatric symptoms, suggesting better tolerability with BIC-based therapy despite the small sample
Introduction: Few data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV).
Methods: We analyzed pooled HIV-1 RT genotypic data from 280 PLWH in the multicenter EuResist database and 115 PLWH in the Stanford HIV Drug Resistance Database (HIVDB) who received RPV as their only NNRTI.
Results: Among the 395 PLWH receiving RPV, 180 (45.
Due to a limited range of effective treatment options, highly treatment-experienced (HTE) people with HIV (PWH) still struggle to maintain virological suppression and obtain an adequate immunological recovery. To increase the likelihood of virologic success, HTE PWH require an individualized treatment regimen based on cumulative genotypic resistance testing (GRT) data, potential drug-drug interactions, and adherence. From the PRESTIGIO Registry, we present a case of a 28-year-old man with vertically transmitted HIV-1 infection, on therapy with an ibalizumab-including regimen and desiring a treatment simplification.
View Article and Find Full Text PDFBackground: Next-generation sequencing (NGS) kits are needed to finalise the transition from Sanger sequencing to NGS in HIV-1 genotypic drug resistance testing.
Materials And Methods: We compared a homemade NGS amplicon-based protocol and the AD4SEQ HIV-1 Solution v2 (AD4SEQ) NGS kit from Arrow Diagnostics for identifying resistance-associated mutations (RAMs) above the 5% threshold in 28 plasma samples where Sanger sequencing previously detected at least one RAM.
Results: The samples had a median 4.
Article Synopsis
- Next-generation sequencing (NGS) is replacing Sanger sequencing for HIV genotypic drug resistance testing, and this study assessed how consistent different interpretation tools are in a real-world setting.
- The research involved analyzing NGS results from 11 Italian labs using the AD4SEQ HIV-1 Solution v2 kit and compared interpretations from SmartVir, HyDRA Web, and Stanford HIVdb.
- Findings indicated that viremia levels and HIV subtypes influence the validity of NGS-GRT, with only mutations present at frequencies over 10% showing reliable agreement among the interpretation tools.